secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001104659-24-013692
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie completes $31.26/share ImmunoGen acquisition; reaffirms FY2024 EPS guidance with $0.42 dilution
--------------------------------------------------------------------------------

- Acquired all outstanding ImmunoGen shares for $31.26 each; ImmunoGen ceases trading on NASDAQ.
- Adds ELAHERE (FRα-positive ovarian cancer ADC) and pipeline assets including IMGN-151 and pivekimab sunirine.
- Reaffirms full-year 2024 adjusted diluted EPS guidance of $11.05-$11.25, now including $0.42 dilution from ImmunoGen and pending Cerevel.
- Updates Q1 2024 adjusted EPS guidance to $2.26-$2.30 from $2.30-$2.34 due to $0.04 dilutive impact from ImmunoGen.
- Expects the acquisition to be accretive to diluted EPS beginning in 2027 and significantly accretive over long term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465924013692/0001104659-24-013692-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465924013692/tm245657d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-013692

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer